Abstract:Purpose: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is an important regulator of necroptosis and inflammatory responses. We present the clinical features, genetic analysis and immune work-up of two patients with infantile-onset inflammatory bowel disease (IBD) resulting from RIPK1 mutations. Methods: Whole exome and Sanger sequencing was performed in two IBD patients. Mass cytometry time of flight (CyTOF) was conducted for in-depth immunophenotyping on one of the patient's peripheral blood mononuclear cells, and compared to control subjects and patients with Crohn's disease. Results: The patients presented with severe colitis and perianal fistulas in the first months of life, without severe/atypical infections. Genetic studies identified pathogenic genetic variants in RIPK1 (Patient 1, A c.1934C>T missense mutation in Exon 11; Patient 2, c.580G>A missense mutation residing in Exon 4). Protein modeling demonstrated that the mutation in Patient 1 displaces a water molecule, potentially disrupting the local environment, and the mutation in Patient 2 may lead to disruption of the packing and conformation of the kinase domain. Immunofluorescence RIPK1 staining in rectal biopsies demonstrated no expression for Patient 1 and minimal expression for Patient 2, compared to controls and patients with active Crohn's disease. Using CyTOF unbiased clustering analysis, we identified peripheral immune dysregulation in one of these patients, characterized by an increase in IFNγ CD8+ T cells along with a decrease in monocytes, dendritic cells and B cells. Moreover, RIPK1-deficient patient's immune cells exhibited decreased IL-6 production in response to lipopolysaccharide (LPS) across multiple cell types including T cells, B cells and innate immune cells. Conclusions: Mutations in RIPK1 should be considered in very young patients presenting with colitis and perianal fistulas. Given RIPK1's role in inflammasome activation, but also in epithelial cells, it is unclear whether IL1 blockade or allogeneic hematopoietic stem cell transplantation can suppress or cure the hyper-inflammatory response in these patients. Additional studies in humans are required to better define the role of RIPK1 in regulating intestinal immune responses, and how treatment can be optimized for patients with RIPK1 deficiency.

RIPK1-Associated Inborn Errors of Innate Immunity

[Research Progress on Receptor Interacting Proteins in Inflammation].

A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1

The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation

RIPK1 deficiency prevents thymic NK1.1 expression and subsequent iNKT cell development

Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death

Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease.

25 years of research put RIPK1 in the clinic

The Latest Information on the RIPK1 Post-Translational Modifications and Functions.

RIPK1 Biallelic Activating Variants lead to Autoinflammatory Disease Driven by T cell Death

Regulation of Innate Immune Responses by Receptor Interacting Protein Kinases (172.43)

RIPK3 signaling and its role in regulated cell death and diseases

Biallelic RIPK1 Mutations in Humans Cause Severe Immunodeficiency, Arthritis, and Intestinal Inflammation

RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis

Regulatory mechanisms of RIPK1 in cell death and inflammation

RIP kinases as modulators of inflammation and immunity

Regulation of RIPK1 Phosphorylation: Implications for Inflammation, Cell Death, and Therapeutic Interventions

Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis

RIP3: a Molecular Switch for Necrosis and Inflammation.

RIPK1 mutations causing infantile-onset IBD with inflammatory and fistulizing features

RIPK1 Dephosphorylation and Kinase Activation by PPP1R3G/PP1γ Promote Apoptosis and Necroptosis.